Skip to main content
SpringerLink
Log in

Can cancer chemotherapy enhance the malignant behaviour of tumours?

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Cancer chemotherapy is currently undergoing an intensive reappraisal because of its unimpressive performance against the major common cancers. There are a number of possible reasons for this lack of success; one considered here is that under some circumstances anti-neoplastic drug treatment actually increases the malignant behaviour of tumours. Support for this idea comes mainly from experimental studies in which drug treatments increased metastatic spread. Investigation of this phenomenon shows that drug induced modifications of the host, including immunosuppression and vascular damage, can indeed facilitate metastasis. In addition, new data are presented demonstrating that the direct action of drugs on the tumour cells themselves can have similar enhancing effects. The possible mechanisms underlying such direct effects are discussed and the ability of anti-cancer drugs to cause genetic mutations, amplify genes, and alter gene expression are considered. While the nature and extent of this facilitation of tumour malignancy is not fully understood, it is suggested that this possibility should be considered in the design of treatment protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kearsley JH: Cytotoxic chemotherapy for common adult malignancies: ‘the emperor's new clothes’ revisited? Brit Med J 293: 871–876, 1986

    Google Scholar 

  2. Cairns J: The treatment of diseases and the war against cancer. Sci Am 253: (5) 31–39, 1985

    Google Scholar 

  3. Bailar JC, Smith EM: Progress against cancer? New Eng J Med 314: 1226–1232, 1986

    Google Scholar 

  4. Feinstein AR, Sosin DM, Wells CK: The Will Rogers Phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New Eng J Med 312: 1604–1608, 1986

    Google Scholar 

  5. Various correspondence, New Eng J Med 315: 963–968, 1986

    Google Scholar 

  6. Kerbel RS, Davies AJS: Facilitation of tumour progression by cancer therapy. Lancet II, 977–978, 1982

    Google Scholar 

  7. van Putten LM, Kram LKJ, van Drerendonck HHC, Smink T, Fuzy M: Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int J Cancer 15: 588–595, 1975

    Google Scholar 

  8. Poupon M-F, Pauwels C, Jasmin C, Antoine E, Lascaux V, Rosa B: Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment. Cancer Treat Rep 68: 749–758, 1984

    Google Scholar 

  9. Tofilon PJ, Basic I, Milas L: Prediction ofin vivo tumor response to chemotherapeutic agents by thein vitro sister chromatid exchange assay. Cancer Res 45: 2025–2030, 1985

    Google Scholar 

  10. Stephens TC, Adams K, Peacock JH: Metastasis of Lewis lung carcinoma regrowing after cytotoxic treatments. In: Hellman K, Hilgard P, Eccles S (eds) Metastasis. Clinical and Experimental Aspects. Martinus Nijhoff Publishers, The Hague, 1980, pp 411–415

    Google Scholar 

  11. Steel GG, Adams K: Enhancement by cytotoxic agents of artificial pulmonary metastasis. Br J Cancer 36: 653–658, 1977

    Google Scholar 

  12. Carmel RJ, Brown JM: The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastasis in mice. Cancer Res 37: 145–151, 1977

    Google Scholar 

  13. Milas L, Malenica B, Allegneti N: Enhancement of artificial lung metastases in mice caused by cyclophosphamide. 1. Participation of impairment of host anti-tumor resistance. Cancer Immunol Immunother 6: 191–196, 1979

    Google Scholar 

  14. Moore JV, Dixon B: Metastasis of a transplantable mammary tumour in rats treated with cyclophosphamide and/or irradiation. Br J Cancer 36: 221–226, 1977

    Google Scholar 

  15. Orr FW, Adamson IYR, Young L. Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury. Cancer Res 46: 891–897, 1986

    Google Scholar 

  16. Stewart RAN, Hacker MP: Enhancement of B16 melanoma pulmonary colonization in mice following bleomycin or hyperoxia. Proc Am Assoc Cancer Res 25: 60, 1984

    Google Scholar 

  17. Saijo N, Ozaki A, Sakurai M, Ishihara J, Takahashi H, Sasaki Y, Hoshi A, Hamburger AW: Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57 BL/6 mice receiving anticancer agent. Jpn J Cancer Res (Gann) 77: 487–493, 1986

    Google Scholar 

  18. Kondo T, Moor GE: Production of metastases by treatment with carcinostatic agents. I Effects of carcinostatic agents on the host. Cancer Res 21: 1396–1399, 1961

    Google Scholar 

  19. Dao TL, Yogo H: Enhancement of pulmonary metastasis by X-irradiation in rats bearing mammary cancer. Cancer 20: 2020–2025, 1967

    Google Scholar 

  20. Hirata H, Tanaka K: Artificial metastases and decrease of fibrinolysis in the nude mouse lung after hemithoracic irradiation. Clin Exp Metastasis 2: 311–319, 1984

    Google Scholar 

  21. Withers HR, Milas L: Influence of pre-irradiation of lung on development of artificial pulmonary metastases of fibrosarcoma in mice. Cancer Res 33: 1931–1936, 1973

    Google Scholar 

  22. Brown JM: The effect of lung irradiation on the incidence of pulmonary metastasis in mice. Brit J Radiol 46: 613–618, 1973

    Google Scholar 

  23. Pizzo PA, Young RC: Infections in the cancer patient. In: Devita VT, Hellman S, Rosenburg SA (eds) Cancer. Principles and Practice of Oncology. J.B. Lippincott Company, Philadelphia, 1985, pp 1963–1998

    Google Scholar 

  24. Rosenberg SA, Terry WD: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323–388, 1977

    Google Scholar 

  25. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA: Lymphokine-activated killer cells: Lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44: 1946–1953, 1984

    Google Scholar 

  26. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Eng J Med 313: 1485–1492, 1985

    Google Scholar 

  27. Hanna N, Fidler IJ: Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 65: 801–809, 1980

    Google Scholar 

  28. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR: Role of natural killer cells in tumor growth and metastasis: C57 BL/6 normal and beige mice. J Natl Cancer Inst 65: 929–935, 1980

    Google Scholar 

  29. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB: Role of natural killer cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30: 107–112, 1982

    Google Scholar 

  30. Saijo N, Shimizu E, Shibuya M, Inrimajiri N, Takizawa T, Eguchi K, Shinkai T, Tominaga K, Shimabujuro Z, Taniguchi T, Hoshi A: Effect of chemotherapy on natural killer activity and antibody-dependent cell mediated cytotoxicity in carcinoma of the lung. Br J Cancer 46: 180–189, 1982

    Google Scholar 

  31. Nolibe D, Poupon MF: Enhancement of pulmonary metastases induced by decreased lung natural killer cell activity. J Natl Cancer Inst 77: 99–103, 1986

    Google Scholar 

  32. Connors TA: Alkylating agents, nitrosoureas and alkyltriazenes. In: Pinedo HM, Chabner BA (eds) Cancer Chemotherapy. Elsevier, Amsterdam, pp 42, 1984

    Google Scholar 

  33. Mantovani A, Luini W, Peri W, Vecchi A, Spreafico F: Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 61: 1255–1261, 1978

    Google Scholar 

  34. Mount D, Bruce WR: Local plasma volume and vascular permeability of rabbit skin after irradiation. Radiation Res 23: 430–445, 1964

    Google Scholar 

  35. Fidler IJ: General considerations for studies of experimental cancer metastasis. In: Bush H (ed) Methods in Cancer Research, Vol. XV. Academic Press, New York, pp 399–439, 1978

    Google Scholar 

  36. Adamson YR, Bowden H: The pathogenesis of bleomycin induced pulmonary fibrosis in mice. Am J Pathol 77: 185–197, 1974

    Google Scholar 

  37. Catravas JD, Lazo JJ, Dobuler KJ, Mills LR, Gillis CN: Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am Rev Resp Dis 128: 740–746, 1983

    Google Scholar 

  38. Nicolson GL, Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 45: 331–336, 1985

    Google Scholar 

  39. Clements GB: Selection of biochemically variant, in some cases mutant, mammalian cells in culture. Adv Cancer Res 21: 273–390, 1975

    Google Scholar 

  40. Frondoza CG, Trividi SM, Humphrey RL: Development and characterization of a cyclophosphamide resistant mouse plasmacytoma cell line. Cancer Treat Rep 66: 1535–1544, 1982

    Google Scholar 

  41. Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST:In vivo resistance towards anthracyclines, etoposide and cisdiamminedichloroplatinum (II). Cancer Res 42: 4719–4725, 1982

    Google Scholar 

  42. Ball CR, Connors TA, Double JA, Ujihazy V, Whisson ME: Comparison of nitrogen-mustard-sensitive and-resistant Yoshida sarcomas. Int J Cancer 1: 319–327, 1966

    Google Scholar 

  43. Giavazzi R, Miller L, Hart IR: Metastatic behaviour of an adriamycin-resistant murine tumor. Cancer Res 43: 5081–5086, 1983

    Google Scholar 

  44. McMillan TJ, Stephens TC, Steel GG: Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan. Br J Cancer 53: 753–759, 1986

    Google Scholar 

  45. Biedler JL, Chang T-D, Meyers MB, Peterson RHF, Sprengler BA: Drug resistance in Chinese hamster lung and mouse tumor cells. Cancer Treat Rep 67: 859–867, 1987

    Google Scholar 

  46. Lazo JS, Ingber DE, Sartorelli AC: Enhancement of experimental metastases by cultured B16 melanoma cells treated with (±)-1,2 bis (3,5-dioxopiperazin-1-yl) propane (ICRF-159) Cancer Res 38: 2263–2270

  47. McMillan TJ, Rao J, Hart IR: Enhancement of experimental metastasis by pretreatment of tumour cells with hydroxyurea. Int J Cancer 38: 61–65, 1986

    Google Scholar 

  48. McMillan TJ, Hart IR: Enhanced experimental metastatic capacity of a murine melanoma following pre-treatment with anticancer drugs. Clin Exp Metastasis 4: 285–292, 1986

    Google Scholar 

  49. Poste G, Doll J, Fidler IJ: Interactions between clonal subpopulations affect the stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci USA 78: 6226–6230, 1981

    Google Scholar 

  50. Poste G: Experimental systems for analysis of the malignant phenotype. Cancer Met Rev 1: 141–199, 1982

    Google Scholar 

  51. Fidler IJ: The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 9: 223–227, 1973

    Google Scholar 

  52. Lione A, Bosmann HB: Quantitative relationship between volume of tumour cell units and their intravascular survival. Br J Cancer 37: 248–253, 1978

    Google Scholar 

  53. Grdina DJ, Hittelman WN, White RA, Meistrich ML: Relevance of density, size and DNA content of tumour cells to the lung colony assay. Br J Cancer 36: 659–669, 1977

    Google Scholar 

  54. Hill RP, Bush RS: A lung-colony assay to determine the radiosensitivity of the cells of a solid tumour. Int J Radiat Biol 15: 435–444, 1969

    Google Scholar 

  55. Steel GG: Growth Kinetics of Tumours. Clarendon Press, Oxford, 1977, pp 233–236

    Google Scholar 

  56. Foulds L: The experimental study of tumour progression: A review. Cancer Res 14: 327–339, 1954

    Google Scholar 

  57. Foulds L: Tumour progression and neoplastic progression. In: Emmelot P, Muhlbock O (eds) Cellular Control Mechanisms and Cancer. Elsevier, Amsterdam, 1964, pp 242–258

    Google Scholar 

  58. Hauschka TS: The chromosomes in ontogeny and oncogeny. Cancer Res 21: 957–974, 1961

    Google Scholar 

  59. Nowell PC: The clonal evolution of tumour cell populations. Science 194: 23–28, 1976

    Google Scholar 

  60. Nowell PC: Genetic instability in cancer cells: relationship to tumor cell heterogeneity. In: Owens AH, Coffey DS, Baylin SB (eds) Tumor Cell Heterogeneity. Academic Press, New York, 1982 pp 351–365

    Google Scholar 

  61. Cifone MA, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci (Wash.) 78: 6949–6952, 1982

    Google Scholar 

  62. Schirrmacher V, Dzarlieva R, Altevogt P, Fogel M, Waller CA, Dennis JW, Springer GF, Vlodavsky I, Kramer M, Cheingsong-Popor R: Phenotypic and genotypic differences between high- and low-metastatic related tumour lines and the problem of tumour progression and variant generation. In: Nicolson GL, Milas L (eds) Cancer Invasion and Metastasis. Raven Press, New York, 1984, pp 81–99

    Google Scholar 

  63. Seshadri R, Kutlaca RJ, Trainor K, Matthews C, Morley AA: Mutation rate of normal and malignant human lymphocytes. Cancer Res 47: 407–409, 1987

    Google Scholar 

  64. Elmore E, Kakunaya T, Barrett JC: Comparison of spontaneous mutation rates of normal and chemically transformed human skin fibroblasts. Cancer Res 43: 1650–1655, 1983

    Google Scholar 

  65. Fisher MS, Cifone MA: Enhanced metastatic potential of murine fibrosarcoma treatedin vitro with ultraviolet radiation. Cancer Res 41: 3018–3023, 1981

    Google Scholar 

  66. Boon T, Kellerman O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma line. Proc Natl Acad Sci USA 74: 272–275, 1977

    Google Scholar 

  67. Boon T, van Pel A: Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunised with these variants, against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75: 1519–1523, 1978

    Google Scholar 

  68. Boon T, van Snick J, van Pel A, Utterhove C, Marchand M: Immunogenic variants obtained by mutagenesis of mouse mastochtoma P815. II T lymphocyte mediated cytolysis. J Exp Med 152: 1184–1193, 1980

    Google Scholar 

  69. Benedict WF, Baker MS, Haroum L, Choi E, Ames BN: Mutagenicity of cancer chemotherapeutic agents in the Salmonella microsome test. Cancer Res 37: 2210–2213, 1977

    Google Scholar 

  70. Anderson KS, Platinum (II) complexes generate frameshift mutations in test strain of Salmonella typhimurium. Mutat Res 67: 209–214, 1979

    Google Scholar 

  71. Singh B, Gupta RS: Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res 43: 577–584, 1983

    Google Scholar 

  72. Balmain A, Ransden M, Bowden GT, Smith J: Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658–660, 1984

    Google Scholar 

  73. Park M, Dean M, Cooper CS, Schmidt M, O'Brien J, Blair DG, Woude GF: Mechanisms of met oncogene activation. Cell 45: 895–904, 1986

    Google Scholar 

  74. Huberman E, Heidelberger C: The mutagenicity to mammalian cells of pyrimidine nucleoside analogues. Mutat Res 14: 130–132, 1972

    Google Scholar 

  75. Landolf JR, Jones PS: Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T1/2 clone 8 and V79 cells. Cancer Res 42: 817–823, 1982

    Google Scholar 

  76. Barker PE: Double minutes in human tumor cells. Cancer Genet Cytogenet 5: 81–94, 1982

    Google Scholar 

  77. Gebhart E, Bruderlein S, Tulusan AH, Maillot KV, Birkmann J: Incidence of double minutes, cytogenetic equivalents of gene amplification, in human carcinoma cells, Int J Cancer 34: 369–373, 1984

    Google Scholar 

  78. George DL: Amplification of cellular protooncogenes in tumours and tumour cell lines, Cancer Surveys 3: 497–513, 1984

    Google Scholar 

  79. Lee WH, Murphee AL, Benedict WF: Expression and amplification of N-myc gene in primary retinoblastoma. Nature 309: 458–460, 1984

    Google Scholar 

  80. Collins SJ, Groudine MT: Rearrangement and amplification of c-alb sequences in human chronic myelogenous leukemia cell line K-562. Genetics 80: 4813–4817, 1983

    Google Scholar 

  81. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM: Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrin cells from a human colon carcinoma. Proc Natl Acad Sci USA 801: 1709–1711, 1983

    Google Scholar 

  82. Pulciani S, Santos E, Long LK, Sorrentino V, Mariano B: Ras gene amplification and malignant transformation. Mol Cell Biol 5: 2836–2841, 1985

    Google Scholar 

  83. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM: Enhanced expression of the human gene N-myc consequence to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 81: 4940–4944, 1984

    Google Scholar 

  84. Yokata J, Tsunetsugo-Yokota Y, Baltifora H, LeFevre C, Cline MJ: Alterations of myc, myb and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 261–265, 1986

    Google Scholar 

  85. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD: Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194–196, 1983

    Google Scholar 

  86. Nau MM, Brooks BJ, Carney DN, Gazdar AF, Battey JF, Sausville EA, Minna JD: Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci USA 83: 1092–1096, 1986

    Google Scholar 

  87. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124, 1984

    Google Scholar 

  88. Ling V, Chambers AF, Harris JF, Hill RP: Dynamic heterogeneity and metastasis. J Cell Physiol suppl 3: 99–103, 1984

    Google Scholar 

  89. Cillo C, Ling V, Hill R: Gene Amplification and Metastasis. Abstract: The Genetics of Development, Honey Harbor, 1985

  90. Brown PC, Tlsty TD, Schimke RT: Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea. Mol Cell Biol 3: 1097–1107, 1983

    Google Scholar 

  91. Tlsty TD, Brown PC, Schimke RT: UV-radiation facilitates methotrexate resistance and amplification of the dihydrofolate reductase gene in cultured 3T6 mouse cells. Mol Cell Biol 4: 1050–1056, 1984

    Google Scholar 

  92. Tlsty TD, Brown PC, Johnston R, Schimke RT: Enhanced frequency of generation of methotrexate resistance and gene amplification in cultured mouse and hamster cell lines. In: Schimke RT (ed) Gene Amplification. Cold Spring Harbor Laboratory, New York, 1982, p 231

    Google Scholar 

  93. Rice GC, Hoy C, Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 83: 5978–5982, 1986

    Google Scholar 

  94. Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature (Lond) 283: 139–146, 1980

    Google Scholar 

  95. Talmadge JE, Fidler IJ: Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 69: 975–980, 1982

    Google Scholar 

  96. Roninson IB: Detection and mapping of homologous, repeated and amplified DNA sequences by DNA renaturation in agarose gels. Nucleic Acids Res 11: 5413–5432, 1983

    Google Scholar 

  97. Schimke RT, Hill A, Johnson RN: Methotrexate resistance and gene amplification: an experimental model for the generation of cellular heterogeneity. Brit J Cancer 51: 459–465, 1985

    Google Scholar 

  98. Giulotto E, Knights C, Stark GR: Hamster cells with increased rats of DNA amplification, a new phenotype. Cell 48: 837–845, 1987

    Google Scholar 

  99. Schimke RT: Gene amplification in cultured animal cells. Cell 37: 705–713, 1984

    Google Scholar 

  100. Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: Origins and implications. Science 217: 998–1003, 1982

    Google Scholar 

  101. Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259–2265, 1984

    Google Scholar 

  102. Takenaga K: Modification of the metastatic potential of tumor cells by drugs. Cancer Met Rev 5: 67–75, 1986

    Google Scholar 

  103. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20: 85–93, 1984

    Google Scholar 

  104. Santi DV, Garrett CE, Barr PJ: On the mechanism of inhibition of DNA cytosine methyltransferases by cytosine analogs. Cell 33: 9–10, 1983

    Google Scholar 

  105. Friedman S: The inhibition of DNA (cytosine-5) methylases by 5 azacytidine. The effect of azacytosine-containing DNA. Mol Pharmacol 19: 314–320, 1981

    Google Scholar 

  106. Vesely J, Cihak A: 5-azacytidine: mechanism of action and biological effects in mammalian cells. Pharmac Ther A 2: 813–840, 1978

    Google Scholar 

  107. Ormerod EJ, Everett CA, Hart IR: Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine. Cancer Res 46: 884–890, 1986

    Google Scholar 

  108. Olsson L, Forchhammer J: Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc Natl Acad Sci USA 81: 3389–3393, 1984

    Google Scholar 

  109. Kerbel RS, Frost P, Liteplo R, Carlow DA, Elliot BE: Possible epigenetic mechanisms of tumor progression: Induction of high frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol Suppl 3: 87–97, 1984

    Google Scholar 

  110. Trainer DL, Kline T, Mallon F, Greig R, Poste G: Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells. Cancer Res 45: 6124–6130, 1985

    Google Scholar 

  111. Taylor SM, Jones PA: Mechanism of action of eukaryotic DNA methyltransferase. J Mol Biol 162: 679–692, 1982

    Google Scholar 

  112. Jones PA, Taylor SM: Hemimethylated duplex DNAs prepared from 5-azacytidine treated cells. Nucleic Acids Res 9: 2933–2947, 1981

    Google Scholar 

  113. Razin A, Riggs D: DNA methylation and gene function. Science (Wash. D.C.) 210: 604–610, 1980

    Google Scholar 

  114. Bird AP: DNA methylation-how important in gene control? Nature (Lond.) 307: 503–504, 1984

    Google Scholar 

  115. Christman JK, Price P, Pedrinan L, Acs G: Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur J Biochem 81: 53–61, 1977

    Google Scholar 

  116. Chandler LA, DeClerck YA, Bogenmann E, Jones PA: Patterns of DNA methylation and gene expression in human tumor cell lines. Cancer Res 46: 2944–2949, 1986

    Google Scholar 

  117. Olsson L, Due C, Diamant M: Treatment of human cell lines with 5-azacytidine may result in profound alterations in clonogenicity and growth rate. J Cell Biol 100: 508–513, 1985

    Google Scholar 

  118. Ormerod EJ, Everett CA, Finch M, Hart IR: DNA methylation levels in human and murine melanoma cell lines of varying metastatic potential. Cancer Res 46: 4342–4345, 1986

    Google Scholar 

  119. Boehm TIJ, Drahovsky D: Alteration of enzymatic methylation of DNA cytosines by chemical carcinogens: A mechanism involved in the initiation of carcinogenesis. J Natl Cancer Inst 71: 429–433, 1983

    Google Scholar 

  120. Ivarie RD, Morris JA, Martial JA: Prolactin-deficient variants of GH3rat pituitary tumor cells: linked expression of prolactin and another hormonally responsive protein in GH3 cells. Mol Cell Biol 2: 179–189, 1982

    Google Scholar 

  121. Farrance IK, Ivarie RD: Ethylation of poly (dC-dG) by ethyl methanesulfonate stimulates the activity of mammalian DNA methyltransferasein vitro. Proc Natl Acad Sci USA 82: 1045–1049, 1985

    Google Scholar 

  122. Nyce JW, Jones PA: Drug induced hypermethylation of DNA sequences within mammalian cells. Proc Amer Ass Cancer Res 27: 12–17, 1986

    Google Scholar 

  123. Seemayer G: Methylation of DNAin vivo by thymus, spleen and liver of the rat. Biochim Biophys Acta 224: 10–20, 1970

    Google Scholar 

  124. Klein G, Klein E: Evolution of tumours and the impact of molecular oncology. Nature 315: 190–195, 1985

    Google Scholar 

  125. Wilson EL, Dowdle E: Secretion of plasminogen activator by normal, reactive and neoplastic human tissues culturedin vitro. Int J Cancer 22: 390–399, 1978

    Google Scholar 

  126. Wang BS, McLoughlin GA, Riche JP, Mannick JA: Correlation of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. Cancer Res 40: 288–292, 1980

    Google Scholar 

  127. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301–305, 1985

    Google Scholar 

  128. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675–678, 1986

    Google Scholar 

  129. Meruelo D, Kornreich R, Rossomando A, Pampeno C, Boral A, Silver JL, Buxbaum J, Weiss EH, Devlin JJ, Mellor AL, Flavell RA, Pellicer A: Lack of class I H-2 antigens in cells transformed by radiation leukemia virus is associated with methylation and rearrangement of H-2 DNA. Proc Natl Acad Sci USA 83: 4504–4508, 1986

    Google Scholar 

  130. Carlow DA, Kerbel RS, Feltis JT, Elliot BE: Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. J Natl Cancer Inst 75: 291–301, 1985

    Google Scholar 

  131. Chen E, Karr RW, Frost JP, Gonwa TA, Ginder GD: Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol and Cell Biol 6: 1698–1705, 1986

    Google Scholar 

  132. Boehm TLJ, Drahovsky D: Elevated level of enzymatic DNA methylation in cells treated with 1-β-D-arabinofuranosylcytosine. Cancer Res 42: 1537–1540, 1982

    Google Scholar 

  133. Stefani S, Eells RW, Abbate J: Hydroxyurea and radiotherapy in head and neck cancer. Radiology 101: 391–396, 1971

    Google Scholar 

  134. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 76: 375–383, 1986

    Google Scholar 

  135. Slotman GJ, Mohit T, Raina S, Swaminathan AP, Ohanian M, Rush BF: The incidence of metastases after multimodal therapy for cancer of the head and neck. Cancer 54: 2009–2014, 1984

    Google Scholar 

Download references

Author information

Author notes

  1. T. J. McMillan

    Present address: Radiotherapy Research Unit, Institute of Cancer Research, SM2 SPX, Sutton, Surrey, UK

Authors and Affiliations

  1. Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, PO Box 123, WC2A 3PX, London, UK

    T. J. McMillan & I. R. Hart

Authors
  1. T. J. McMillan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. R. Hart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McMillan, T.J., Hart, I.R. Can cancer chemotherapy enhance the malignant behaviour of tumours?. Cancer Metast Rev 6, 503–520 (1987). https://doi.org/10.1007/BF00047465

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047465

Key words

Search

Navigation